Onconova is focused on discovering and developing novel products for patients with cancer.
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.
Onconova’s novel, proprietary multi-kinase inhibitor narazaciclib (ON 123300) is being evaluated in two separate and complementary Phase 1 dose-escalation and expansion studies. These trials are currently underway in the United States and China. Onconova’s product candidate oral rigosertib is being investigated as a single agent therapy for RDEB-associated squamous cell carcinoma and in combination with PD1 checkpoint inhibitors in IO-refractory KRAS mutated non-small cell lung cancer and malignant melanoma.
Onconova Therapeutics was incorporated in 1998 in Delaware and began trading on the NASDAQ stock exchange under the ticker symbol ONTX in July, 2013.